» Articles » PMID: 2787408

Lack of Interference by the Unnatural Isomer of 5-formyltetrahydrofolate with the Effects of the Natural Isomer in Leucovorin Preparations

Overview
Specialty Oncology
Date 1989 Aug 2
PMID 2787408
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Leucovorin, a mixture of the natural (6S) and unnatural (6R) diastereomers of 5-formyltetrahydrofolate, is administered clinically to enhance the antitumor activity of 5-fluorouracil. Because the 6R isomer persists at high concentrations in plasma for prolonged periods after iv leucovorin administration (J Clin Oncol 4:685-696, 1986), we have examined it to ascertain whether the 6R isomer could interfere with the cellular effects of the 6S isomer. The 6R compound had a poorer uptake into human CCRF-CEM lymphoblastic cells than the 6S compound, but the 6R compound could competitively inhibit the uptake of the natural isomer as determined in defined buffers. However, the 6R compound failed to interfere with cell growth support and enhancement of 5-fluorouracil cytotoxicity by the 6S isomer in CCRF-CEM cells in tissue culture experiments at concentrations up to 1 mM. Thus, the unnatural isomer of 5-formyltetrahydrofolate present in leucovorin preparations seems unlikely to have clinically relevant consequences.

Citing Articles

The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity.

Peters G, Kathmann I, Giovannetti E, Smid K, Assaraf Y, Jansen G Front Pharmacol. 2024; 15:1450418.

PMID: 39234107 PMC: 11371747. DOI: 10.3389/fphar.2024.1450418.


Regulation of T cell proliferation with drug-responsive microRNA switches.

Wong R, Chen Y, Smolke C Nucleic Acids Res. 2017; 46(3):1541-1552.

PMID: 29244152 PMC: 5815133. DOI: 10.1093/nar/gkx1228.


Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.

Stremetzne S, Streit M, Kreuser E, Schunack W, Jaehde U Pharm World Sci. 1999; 21(4):184-9.

PMID: 10483607 DOI: 10.1023/a:1008671129128.


A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.

Meropol N, Petrelli N, Rustum Y, Rodriguez-Bigas M, Blumenson L, Frank C Invest New Drugs. 1995; 13(2):149-55.

PMID: 8617578 DOI: 10.1007/BF00872864.


Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.

Valone F, Gandara D, Luce J, Wall S, Perez E, Braham N Cancer Chemother Pharmacol. 1993; 32(3):215-20.

PMID: 8500227 DOI: 10.1007/BF00685838.